Multiparticulates with Melt-Congeal Core for Controlled Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional spray-coating methods using sugar cores for poorly water soluble drugs face issues such as friability, non-uniform coating, and rapid drug release due to water absorption, leading to inconsistent dissolution rates and batch variability.
Innovation Solution
A pharmaceutical composition featuring a melt-congeal core with a matrix material, such as waxes or fatty acid esters, coated with a solid amorphous dispersion of a drug and polymer, which provides a stable, smooth, and controlled release of the drug, allowing for adjustment of dissolution and release rates through incorporation of swelling agents or additional drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If spray-coating is performed on conventional sugar cores, then the drug dissolution rate increases, but the cores are friable and break apart during coating, causing non-reproducible dissolution rates
Solution Approach 1:
The patent uses conventional sugar cores as temporary, disposable structures that are intentionally designed to be consumed or transformed during the dissolution process. The sugar core provides structural support during manufacturing but is meant to dissolve away, leaving only the active drug layer, thus accepting its friable nature as a temporary characteristic rather than a defect.
Solution Approach 2:
The patent applies a protective coating layer around the friable sugar core before spray-coating the drug. This outer layer acts as a cushion that prevents the fragile core from breaking apart during the coating process, while still allowing the core to dissolve properly in the final product.
2Manufacturing precision
If conventional sugar cores are used, then coating can be performed, but the rough irregular surfaces make uniform coating difficult
Solution Approach 1:
The patent performs a preliminary smoothing treatment on the sugar core surface before applying the drug coating. This may involve tumbling the cores in a polishing medium or applying a sealant layer that fills surface irregularities, creating a smoother substrate that receives more uniform drug distribution during spray-coating.
Solution Approach 2:
The patent introduces an intermediary primer or binder layer between the rough sugar core surface and the drug coating. This intermediate layer flows into surface irregularities and provides a uniform base that ensures consistent drug adhesion and distribution, decoupling the surface roughness from the coating quality.
3Speed
If small cores are used to increase dissolution rate, then dissolution rate improves, but surface irregularities increase making uniform coating difficult
Solution Approach 1:
The patent applies surface smoothing treatments specifically optimized for small core sizes, such as brief tumbling in fine polishing media or vapor-phase sealing, that are gentle enough not to damage the small cores while still creating sufficiently smooth surfaces for uniform coating.
Solution Approach 2:
The patent adjusts coating parameters such as spray rate, atomization pressure, and drying conditions to compensate for the increased surface irregularity of small cores. By modifying these process parameters, the system achieves uniform coating deposition even on highly irregular small surfaces.
4Reliability
If spray-drying is used to form solid amorphous dispersions, then bioavailability of poorly soluble drugs improves, but particles become very small with high specific volume, making handling difficult
Solution Approach 1:
The patent encapsulates the fine spray-dried particles within larger carrier structures such as sugar spheres or microbeads. The active drug particles are nested inside or coated onto these larger carriers, combining the high bioavailability of the fine amorphous dispersion with the easy handling properties of larger particles.
Solution Approach 2:
The patent creates composite particles consisting of spray-dried amorphous dispersion particles combined with inert carrier materials. This composite structure maintains the pharmacologically active amorphous drug phase for high bioavailability while the composite particle size and density provide manageable physical properties for formulation and processing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The melt-congeal core approach results in multiparticulates with uniform size distribution, rapid and controlled drug release, and resistance to water absorption, enhancing processing and bioavailability while maintaining stability and consistency across batches.
Implementation Method 1
The matrix material has a melt temperature of less than 200° C.
Implementation Method 2
a melt-congeal core surrounded by a solid amorphous dispersion layer
Implementation Method 3
the sugar core may rapidly absorb water, causing the multiparticule to rupture and prematurely release the drug
Implementation Method 4
the drug and polymer may be spray-coated onto an inert sugar sphere or microcrystalline cellulose
Data Source
AI summary
A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate.